comparemela.com

Latest Breaking News On - Tyr pharma - Page 6 : comparemela.com

Short Interest in aTyr Pharma, Inc (NASDAQ:LIFE) Decreases By 44 0%

aTyr Pharma, Inc. (NASDAQ:LIFE – Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 99,400 shares, a decrease of 44.0% from the January 15th total of 177,500 shares. Based on an average daily trading volume, of 399,300 […]

United statesGranite bay wealth managementCapital partnersAmerican century companies incAtyr pharma incTyr pharmaGet free reportBay wealth managementCentury companiesFire capitalTyr pharma priceTyr pharma dailyAtyr pharmaNasdaq life

After losing 23% in the past year, aTyr Pharma, Inc (NASDAQ:LIFE) institutional owners must be relieved by the recent gain

Key Insights Institutions' substantial holdings in aTyr Pharma implies that they have significant influence over the.

Atyr pharma incHermes incTyr pharmaFederated hermesLogos global managementAtyr pharmaInstitutional investorsNsider ownershipNstitutional ownership

aTyr Pharma, Inc (NASDAQ:LIFE) Receives Average Rating of Moderate Buy from Analysts

aTyr Pharma, Inc (NASDAQ:LIFE) Receives Average Rating of Moderate Buy from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesAtyr pharma incBlackrock incSamsara biocapitalAlyeska investment groupTyr pharmaGet free reportTyr pharma stock downGet freeTyr pharma daily

Global Scleroderma Market Forecasts Promising Growth with

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) The

United statesEli lillyTeva pharmaceutical industries ltdCorbus pharmaceuticals holdings incAspen pharmacare holdingsKadmon holdings incAstellas pharma incCumberland pharmaceuticals incTakeda pharmaceutical companyBoehringer ingelheim international gmbArgentis pharmaceuticalsAbbvie incBristol myers squibb companyPfizer incPrincipia biopharma corpGilead sciences inc

aTyr Pharma, Inc (NASDAQ:LIFE) Receives $20 75 Consensus Target Price from Analysts

aTyr Pharma, Inc (NASDAQ:LIFE) Receives $20 75 Consensus Target Price from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesSamsara biocapitalVanguard group incAtyr pharma incAlyeska investment groupBlackrock incTyr pharmaGet free reportVanguard groupTyr pharma trading downGet freeTyr pharma daily

vimarsana © 2020. All Rights Reserved.